Cendakimab (anti-IL-13) (C007B-446345)

Cendakimab (anti-IL-13) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab (anti-IL-13) has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab (anti-IL-13) recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab (anti-IL-13) has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).Purity:>95% (SDS-PAGE&SEC):Endotoxin Level:< 1.0EU/mg. Specification: ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot

UPC:

51202405

Condition:

New

Weight:

1.09 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

Ab182808-1mg

CAS:

2151032-62-9

Product Size:

1mg